recwt1-A10 + AS01B

recwt1-A10 + AS01B is a therapeutic cancer vaccine candidate composed of the recombinant WT1 protein fragment (recwt1-A10) formulated with the immunostimulatory adjuvant system AS01B. The vaccine is designed as a shared antigen/therapeutic vaccine to stimulate an immune response against tumors expressing the Wilms' tumor 1 (WT1) antigen. The mechanism of action involves immunostimulation, aiming to enhance both T cell-mediated and antibody-mediated immunity against WT1-expressing malignant cells. The combination has been investigated primarily in patients with hematologic malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and Philadelphia chromosome positive chronic myelogenous leukemia (CML), particularly after allogeneic stem cell transplantation[1]. AS01B is a liposome-based adjuvant containing two key immunostimulants—3-O-desacyl-4'-monophosphoryl lipid A (MPL) and QS-21 saponin—which synergistically activate innate immunity via Toll-like receptor 4 signaling and inflammasome activation, leading to robust adaptive immune responses[6][8]. The developer for this specific combination is Institut Jean Paoli & Irene Calmettes[1].

Other names

recwt1-A10 adjuvant with AS01Brecwt-1-A10 adjuvant with AS01Brecwt 1-A10 adjuvant with AS01B